Clinical trials: fluorouracil
Unresectable Locally Recurrent Rectal Cancer
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
This is a prospective study to delve into the therapeutic benefits of combining stereotactic body radiation therapy (SBRT) with PD-1 monoclonal antibody treatment for patients with unresectable locally recurrent rectal cancer…
- Trial name
- NCT06767007
- Testing
- Stereotactic Body Radiation Therapy (SBRT), PD1, Chemotherapy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Breast Cancer, Pregnancy
Primary Breast Cancer Occurring Concomitant With Pregnancy
The goal of this clinical research study is to learn the results of multimodality (chemotherapy, surgery and radiation therapy) treatment of primary breast cancer that occurs at the same time as pregnancy.
- Trial name
- NCT00510367
- Testing
- 5-Fluorouracil, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Cognitive/Functional Effects, Colorectal Cancer
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
This randomized phase III trial studies how well combination chemotherapy plus bevacizumab with or without oxaliplatin works in treating older patients with colorectal cancer that has spread to other places in the body.
- Conditions
- Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT01279681
- Testing
- bevacizumab, capecitabine, fluorouracil
- Volunteers
- 32 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bile Duct Cancer
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours
Bile duct tumours are rare. They are the 6th most common type of digestive cancer. Their therapeutic management is complex and must be multidisciplinary in nature.
- Trial name
- AMEBICA (NCT02591030)
- Testing
- GEMCIS, mFolfirinox
- Where
- 42 sites in France
- Volunteers
- 191 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Rectal Cancer, Colon Cancer
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab.
- Conditions
- Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
- Trial name
- NCT01206530
- Testing
- Hydroxychloroquine, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Stomach Neoplasms, Gastric Cancer
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer.
- Conditions
- Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach
- Trial name
- Neo-ICEBOAT (NCT06451211)
- Testing
- Tislelizumab, Oxaliplatin, S-1
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer, Gastroesophageal Junction Cancer
GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)
This is a prospective, non-interventional, observational, multicentre study evaluating the real-world effectiveness and safety of AstraZeneca-developed and approved medicines used to treat gastric and/or oesophageal cancers in…
- Trial name
- GRACE-DE (NCT07882212)
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Neoplasm, Colorectal Cancer
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
The main clinical hypothesis is that compared to radio-chemotherapy for low and mid rectal tumors or surgery for high rectal tumors neoadjuvant chemotherapy reduces the rate of distant relapse without increasing the rate of local…
- Conditions
- Colorectal Neoplasm, Colorectal Cancer, Rectal Neoplasms, Chemotherapy Effect
- Trial name
- NEOLAR (NCT03280407)
- Testing
- Capecitabine, FOLFOX regimen (oxaliplatin/leucovorin/5FU), CAPOX (oxaliplatin/capecitabine)
- Where
- Denmark
- Volunteers
- 124 people
- Sponsor
- Zealand University Hospital
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005036
- Testing
- irinotecan hydrochloride, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Breast Cancer
Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer
This study was designed to compare the efficacy and safety of an oral dual tyrosine kinase inhibitor in combination with capecitabine versus capecitabine alone in women with locally advanced or metastatic breast cancer that has…
- Trial name
- NCT00078572
- Testing
- capecitabine, lapatinib (GW572016)
- Volunteers
- 408 people
- Sponsor
- GlaxoSmithKline
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available…
- Trial name
- ASCENT-07 (NCT05840211)
- Testing
- Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel
- Where
- 288 sites in United States, Argentina and 26 more
- Volunteers
- 654 people
- Sponsor
- Gilead Sciences
Gastric Cancer
Study of Weekly DCF to Treat Advanced Gastric Cancer
The purpose of this study is to evaluate the efficacy of weekly docetaxol combined with cisplatin and 5-Fu in patients with AGC.
- Trial name
- NCT00568971
- Testing
- Docetaxel, Cisplatin, 5-Fu
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Photoaging, Actinic Keratosis
5fluorouracil for Advanced Photoaging
It is well known the efficacy of 5% 5-fluoruracil for multiple and superficial actinic keratosis (AKs)treatment. Recently its additional benefit for advanced and severe photoaging while treating Aks was reported.
- Trial name
- NCT01405144
- Testing
- 5-fluoruracil
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
Rectal Cancer
Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer
Irinotecan is one of effective drugs for colorectal cancer. In neoadjuvant chemoradiotherapy (CRT), Irinotecan is prescribed in a low dose of 50mg/m2/week because of toxicity.
- Trial name
- NCT01474187
- Testing
- Irinotecan, Capecitabine, Radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Colonic Neoplasms, Neoadjuvant Therapy
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
Building on earlier exploratory work, this study further designs a multi-institutional, prospective, randomized clinical trial to evaluate the efficacy and safety of the combination therapy of the immune checkpoint inhibitor…
- Conditions
- Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- NCT07132008
- Testing
- Tislelizumab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 94 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Hepatocellular Carcinoma (HCC)
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Study Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT.
- Trial name
- NCT07012798
- Testing
- Durvalumab, Bevacizumab, HAIC of FOLFOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Resected Colon Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug is a way to kill more tumor cells.
- Trial name
- NCT00378716
- Testing
- 5-fluorouracil, leucovorin calcium, tegafur
- Volunteers
- 1,608 people
- Sponsor
- NSABP Foundation Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.